J.P. Morgan Maintains Buy Rating on Solid Biosciences
J.P. Morgan analyst Anupam Rama has maintained a "Buy" rating on Solid Biosciences (SLDB) and set a price target of $11.
Stocks · News reference
The European Commission has granted Orphan designation to Solid Biosciences' SGT-212 for the treatment of Friedreich's ataxia, while the company reports continued progress in its Phase 1b FALCON clinical trial.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
J.P. Morgan analyst Anupam Rama has maintained a "Buy" rating on Solid Biosciences (SLDB) and set a price target of $11.
Circio Holding ASA has entered into a collaboration with Solid Biosciences to advance the development of a gene therapy candidate for genetic heart disease.
William Blair analyst Alethia Young initiated coverage on Solid Biosciences (SLDB) with a Buy rating and a price target of $11.
Solid Biosciences announced that its President and CEO, Bo Cumbo, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.